News & Updates

What’s new in the 2025 ACS Guidelines?

The American College of Cardiology and the American Heart Association (ACC/AHA) have issued new guidelines for managing acute coronary syndromes (ACS), outlining strategies for lipid management, minimizing bleeding risk, and considerations related to procedural care.

Caution urged when prescribing NSAIDs in pregnancy in relation to kidney health in offspring

Prenatal exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) has the potential to harm the offspring’s kidney health, highlighting the need for caution when prescribing NSAIDs during pregnancy, according to a large study from Taiwan.

Elacestrant shows promising antitumour activity in early breast cancer

Preoperative treatment with the oral nonsteroidal selective ER degrader elacestrant appears to yield biological and molecular responses in early-stage breast cancer, while having a manageable safety profile, as shown in a phase I trial.

Momelotinib: A game-changer for managing myelofibrosis with anaemia

On November 1, 2024, the Singapore Health Sciences Authority (HSA) approved momelotinib for treating myelofibrosis in adult patients with moderate-to-severe anaemia who are either JAK inhibitor-naïve or have been treated with ruxolitinib. The approval was based on data from three pivotal trials — SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM. [Health Sciences Authority. Momelotinib (Omjjara) product information leaflet 2024]

This article explores the burden of anaemia in myelofibrosis, the evidence supporting momelotinib, and insights from renowned expert Dr Yvonne Loh, Haematologist at Curie Oncology, Singapore, on the challenges of treating myelofibrosis and momelotinib’s evolving role. 

Esketamine may work against treatment-resistant depression

Treatment with esketamine as an add-on to antidepressants shows modest efficacy in adults with treatment-resistant depression, reports a study. Its effect on suicidality, however, is not significant.

Original New Drug Application Approvals by US FDA (1-15 March 2025)

New drug applications approved by US FDA as of 1-15 March 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Ganciclovir/valganciclovir tied to adverse effects in preterm infants with CMV

Preterm and very low birthweight (VLBW) infants who have been treated with ganciclovir (GCV) or oral valganciclovir (valGCV) for cytomegalovirus (CMV) disease are more likely to experience adverse events than term infants, a study has shown.

Cetuximab linked to pocket infections after central venous port placement

Cetuximab therapy appears to induce skin complications in patients following central venous port placement, reports a study.